PhytoMedical Technologies - About PhytomMedical

Click here for Press Release Archive
10/06/2008 Business Wire	PhytoMedical Renews Sponsored Research Agreement with Dartmouth College PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that it is renewing its Sponsored Research Agreement with Dartmouth College. "I am extremely pleased to have extended our agreement with Dartmouth College," stated Mr. Greg Wujek, President and CEO of PhytoMedical Technologies, Inc. " This past year, Dr. Gordon Gribble and his staff have worked very hard to assure all of our developmental goals were accomplished on time allowing us to move from the initial human cancer cell line in vitro testing to our current development phase seamlessly". Dartmouth Technology Transfer Office Assistant Director, Glennis Gold affirmed, "Our collaboration with PhytoMedical is an excellent example of how technology arising out of academia may be transferred to the private sector in order to serve the public good."
08/11/2008 Business Wire	PhytoMedical Acquires Worldwide License Rights to Patented Novel Anti-Cancer Compounds from Dartmouth College PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that it has entered into an exclusive worldwide license agreement with Dartmouth College to develop, market and distribute new anti-tumor bis-acridines, bis-ellipticines and bis-carbazoles known as intercalating agents developed by leading researcher, Dr. Gordon Gribble, of Dartmouth College.
04/14/2008 Business Wire	PhytoMedical Expands Anti-Cancer Research with Important Efficacy Tests PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that a series of positive outcomes from the Company’s ongoing development of its patented anti-cancer compounds have prompted researchers to now undertake their first-ever efficacy studies, an important advancement in the drug development process.
03/17/2008 Business Wire	PhytoMedical Advances Research of Patented Anti-Cancer Compound with Important Toxicity Tests PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that the Company will initiate the third phase of its drug development program, with researchers undertaking important toxicity studies of several select, patented anti-cancer compounds shown to successfully kill cells associated with several difficult-to-treat human cancers.
03/03/2008 Business Wire	PhytoMedical’s Latest Anti-Cancer Compounds Kill Human Colon Cancer Cells PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced positive results from new tests of the Company’s patented ‘next generation’ anti-cancer compounds, which have demonstrated the ability to kill difficult-to-treat human cancer cells, including colon cancer cells and human glioblastoma cells related to brain cancer, an often fatal form of cancer.
02/04/2008 Business Wire	PhytoMedical Bolsters Cancer Research Following Favorable Results PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that favorable research outcomes from ongoing tests have spurred immediate expansion of the Company’s cancer research program, actively working to develop patented, next-generation anticancer compounds targeting multiple human cancer strains.
01/22/2008 Business Wire	PhytoMedical’s Patented Anti-Cancer Compounds Kill Lung Cancer Cells, a Significant New Finding PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6) today announced that its patented bis-intercalator anti-cancer compound achieved a 50% or greater cancer cell kill rate in new in vitro studies of the DMS 114 strain of human small lung cancer cells, an important outcome given lung cancer’s high mortality rate and the lack of effective treatment options.
01/03/2008 Business Wire	PhytoMedical’s Anti-Cancer Compound Effective at Killing Brain Cancer Cells. PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that research outcomes from ongoing in vitro studies of the Company’s sponsored anti-cancer compounds have successfully demonstrated the ability to kill a strain of human brain cancer cells which is otherwise highly-resistant to currently available drugs.